Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors:  Safety, Efficacy, and Biomarkers.

Yakun WangTianshu LiuGongyan ChenJifang GongYuxian BaiTao ZhangNong XuLi LiuJianming XuJianxing HeYunpeng LiuLi ZhangDa JiangMengzhao WangJianhua ChangWei LiChunmei BaiJinghong ZhouJian WangYongxin RenLiya ZhangWeiguo SuBaorui LiuLin Shen

Published in: The oncologist (2022)

NCT0198555.

Keyphrases

tyrosine kinase